Fighting the war on brain cancer with NovoCure chairman Bill Doyle

Novocure, the St. Helier, Jersey-based medical device company, which raised more than $158M in an IPO last year, is trying to change the way we fight cancer. Company officials say its proprietary tumor treating fields technology, marketed under the product name Optune, are a new tool in the war against some of the deadliest forms of cancer. MassDevice publisher Brian Johnson recently caught up with Doyle to discuss the technology, the company's origins and how its current concentration on glioblastoma is just the beginning.

There are no comments yet.

Please log in to write the first comment.